PR Newswire | Aug 31, 2020 08:21PM EDT

08/31 19:10 CDT

SHAREHOLDER ALERT: WeissLaw LLP Investigates Akcea Therapeutics, Inc. NEW YORK, Aug. 31, 2020

NEW YORK, Aug. 31, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Akcea Therapeutics, Inc. ("AKCA" or the "Company") (NASDAQ: AKCA) in connection with the proposed interested-party acquisition of the Company by Ionis Pharmaceuticals, Inc. ("IONS") (NASDAQ: IONS), pursuant to which IONS will acquire all of the minority shares of AKCA that it does not already own. Under the terms of the acquisition agreement, which is structured as a tender offer, the Company's shareholders will receive $18.15 in cash for each share of AKCA common stock that they own.

If you own AKCA shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:

http://www.weisslawllp.com/akcea-therapeutics-inc/

Or please contact:Joshua Rubin, Esq.WeissLaw LLP1500 Broadway, 16th FloorNew York, NY 10036(212) 682-3025(888) 593-4771stockinfo@weisslawllp.com

In light of the fact that IONS already controls 76% of AKCA's common stock, WeissLaw is investigating whether AKCA's board was truly independent and fully informed as to the valuation of the proposed acquisition of the Company, whether the board acted to maximize shareholder value prior to entering into the acquisition agreement, and whether all information regarding the valuation of the deal will be fully and fairly disclosed to AKCA shareholders. Notably, at least one analyst set a price target of $41.00 per AKCA share, or $22.85 above the per-share offer price.

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com

View original content to download multimedia: http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-akcea-therapeutics-inc-301121376.html

SOURCE WeissLaw LLP